Johnson Matthey

Activities: Manufacturing Ingredients Sustainability Research & Development Analysis Digital Pharmaceutical

As leaders in the complex science behind a wide variety of healthcare products, our expertise helps relieve symptoms in millions of people each year.

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Hi Tech Manufacturing

Johnson Matthey agrees to sell Medical Device Components business

The business has been sold to Montagu Private Equity for USD $700m
Sustainability

Johnson Matthey partners with Basecamp Research to accelerate the adoption of biocatalysis solutions

Expanding biocatalyst solutions will reduce energy use and waste in pharmaceutical and agrochemical industries
Manufacturing

JM Health rebrands as Veranova following sale to Altaris Capital Partners

Veranova, formerly known as Johnson Matthey Health, has launched as an independent company following the acquisition by Altaris Capital Partners, LLC from Johnson Matthey PLC
Manufacturing

Johnson Matthey signs long-term supply agreement

The supply deal has been signed to support RNA-based programmes to treat Duchenne muscular dystrophy
Pharmaceutical

Johnson Matthey and Immunomedics join forces on cancer treatment

A strategic manufacturing partnership has been announced for key ingredient of FDA priority review candidate
Manufacturing

JM to offer a new process to synthesise CBD

Johnson Matthey to offer a new process to synthesise ultra-pure cannabidiol, expanding on existing cannabinoid offerings
Media

JM secures Company of the Year 2018 at UK CIA Awards

The judges cited commitment to investment in the UK, its extensive programme of scientific collaborations and recent developments in next generation battery technologies to enable cleaner transportation as reasons for awarding the speciality chemicals company
Subscribe now